. Author manuscript; available in PMC: 2013 May 6.

Published in final edited form as: Clin Cancer Res. 2009 Nov 3;15(22):7099–7105. doi: 10.1158/1078-0432.CCR-09-1722

Table 4.

Hormone levels at baseline and percentage change at month 1 according to PSA response at 3 months

Hormone	Baseline			Percentage change from baseline to month 1
Hormone	PSA responders	PSA nonresponders	P^*	PSA responders	PSA nonresponders	P^*
Patients, n	20	21		14	16
Androstenedione (ng/mL)	0.82 (0.6, 1.18)	0.85 (0.63, 0.98)	0.98	−58 (−73, −43)	−56 (−77, −45)	0.82
DHEAS (ng/mL)	840 (397, 1,145)	480 (311, 1,491)	0.56	−93 (−95, −85)	−85 (−91, −61)	0.1
Testosterone (ng/mL)	0.33 (0.26, 0.50)	0.39 (0.23, 0.47)	0.91	−66 (−74, −56)	−61 (−70, −49)	0.29
DHT^† (pg/mL)	2.3 (<2.0, 3.7)	3 (<2.0, 4.0)	0.63

NOTE: Median and interquartile range (25th, 75th percentiles).

P value by Wilcoxon rank-sum test comparing PSA responders versus PSA nonresponders.

^†

For DHT, at baseline, n = 16 and 17 for PSA responders and nonresponders, respectively, and n = 16 and 15 for percent change from baseline to month 1, respectively.